Lancashire and South Cumbria
Cancer Network

Chemotherapy protocol

Drug regimen
Single agent carboplatin

Indications for use
Ovarian cancer
Primary peritoneal cancer
Fallopian tube cancer
Endometrial cancer

Regimen
Carboplatin AUC 6 in 500mls 5% Glucose over 1 hour

N.B. AUC 5 (Calvert formula) for patients with poor general condition or who have been extensively pre-treated

Repeat every 3 weeks for 6 cycles

Investigation prior to initiating treatment
FBC
Calculated creatinine clearance
LFTs
CA125

Cautions
The Calvert formula is not considered reliable if the creatinine clearance is <40 ml/min. However, prescribing according to surface area leads to excessive doses. Therefore, even in those patients with renal impairment the Calvert formula will be used and doses modified subsequently up or down depending on blood counts.

Investigations and consultations prior to each cycle
FBC
U&E
If serum creatinine raises>20% repeat calculated creatinine clearance before the next cycle
CA125 To be looked at retrospectively
LFT
Consultation needed prior to each cycle

Acceptable limits for treatment to proceed (if outside these delay one week or contact consultant)

If Neutrophils 1.2 – 1.5 contact **consultant**

Delay treatment 1 week or until platelets $\geq$ 100 and neutrophils $\geq$ 1.5
If serum creatinine raises>20% repeat calculated creatinine clearance before the next cycle

Side effects
Hypersensitivity reactions (usually after > 6 cycles)
Alopecia (very occasionally)
Nausea and vomiting
Bone marrow suppression
Flushing effects

Dose Modification Criteria
20% dose reduction if there is a delay > 1 week, if there has been a previous delay of more than 2 cycles or if the patient experiences neutropenic sepsis

Formulas

Calvert formula: (Cl_{Cr} (ml/min) + 25) x AUC

Cockcroft and Gault (for calculating creatinine clearance)

Female $\frac{(140 - \text{age(yrs)}) \times \text{wt(kg)} \times 1.04}{\text{Serum creatinine (micromol/lt)}}$

Male $\frac{(140 - \text{age(yrs)}) \times \text{wt(kg)} \times 1.23}{\text{Serum creatinine (micromol/lt)}}$

THIS PROTOCOL HAS BEEN DIRECTED BY DR HINDLEY, DESIGNATED LEAD CLINICIAN FOR GYNAECOLOGICAL CANCER

RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

DATE **November 2012**
REVIEW **November 2014**
VERSION **13**